BVXV BiondVax Pharmaceuticals Ltd. -

8.85
+0.05  (1%)
Previous Close 8.80
Open 8.92
Price To book 4.31
Market Cap 35.95M
Shares 4,062,000
Volume 26,234
Short Ratio 1.44
Av. Daily Volume 73,778

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b enrollment commenced March 2016. Last patient visit September, 2016.
M-001
Universal flu vaccine

Latest News

  1. European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative
  2. Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials
  3. BVXV: Immunogenicity Results From Phase 2b Trial of M-001 Expected Soon…
  4. BiondVax Announces First Quarter 2017 Financial Results and Update
  5. BVXV: Awarded Grant to Build Commercial Scale Facility for Production of M-001
  6. BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update
  7. BiondVax Gets Approval to Build Plant in Israel
  8. BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
  9. BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal
  10. BVXV: New Publication Shows M-001 Incites Immune Protection Against Current and Future Influenza Strains
  11. Back to the Future: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't yet Exist
  12. BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd.
  13. BVXV: Phase 2b Trial Shows M-001 is Safe and Well Tolerated
  14. BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated
  15. BiondVax Announces Third Quarter 2016 Financial Results and Update
  16. Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains
  17. BiondVax Phase 2b European Trial: Last Patient Out
  18. Professor Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board
  19. BiondVax Announces Second Quarter 2016 Financial Results and Update
  20. BiondVax Invited to WHO Influenza Vaccine Meeting